Primmune Therapeutics

Series-B
primmunerx.com Biotech & Healthcare
Total Funding Undisclosed
Latest Round Undisclosed Series-B
Last Announced Jan 26, 2026
Investors Undisclosed
Decision Makers Profile Active

About Primmune Therapeutics

Develops oral small-molecule TLR7 agonists for systemic cancer immunotherapy.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B
Global Headquarters Undisclosed
Tracked Since Nov 6, 2026

Web & Domain Identity

Official Website primmunerx.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

1 Events
  1. Capital Raise

    Raised undisclosed · Series-B

    fundraisingfox.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Primmune Therapeutics.

Funding History

1 Round
Series-B equity · Jan 26, 2026

Founders & Leadership

2

James Appleman

SVP, R&D and CSO Cofounder, Director

Work email & phone locked Unlock →

Paulo Rangel

Chief Business Officer and Cofounder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts